CN100342872C - A skin caring preparation for treating dermatoses, and its preparation method - Google Patents
A skin caring preparation for treating dermatoses, and its preparation method Download PDFInfo
- Publication number
- CN100342872C CN100342872C CNB2005102005388A CN200510200538A CN100342872C CN 100342872 C CN100342872 C CN 100342872C CN B2005102005388 A CNB2005102005388 A CN B2005102005388A CN 200510200538 A CN200510200538 A CN 200510200538A CN 100342872 C CN100342872 C CN 100342872C
- Authority
- CN
- China
- Prior art keywords
- grams
- ethanol
- preparation
- leaching liquid
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 208000017520 skin disease Diseases 0.000 title abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims abstract description 13
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000282 metronidazole Drugs 0.000 claims abstract description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 9
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 9
- 238000002386 leaching Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 17
- 229940097572 chloromycetin Drugs 0.000 claims description 12
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 10
- 229960001380 cimetidine Drugs 0.000 claims description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 8
- 229960003276 erythromycin Drugs 0.000 claims description 4
- 239000004099 Chlortetracycline Substances 0.000 claims description 3
- 241000245240 Lonicera Species 0.000 claims description 3
- 241001570521 Lonicera periclymenum Species 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims description 3
- 229960004475 chlortetracycline Drugs 0.000 claims description 3
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims description 3
- 235000019365 chlortetracycline Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 206010000496 acne Diseases 0.000 abstract description 7
- 201000004624 Dermatitis Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 206010016936 Folliculitis Diseases 0.000 abstract description 3
- 208000003251 Pruritus Diseases 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 3
- 230000001815 facial effect Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 241000238876 Acari Species 0.000 abstract 1
- 208000020154 Acnes Diseases 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract 1
- 244000247747 Coptis groenlandica Species 0.000 abstract 1
- AEMHIRVQSGPNJA-UHFFFAOYSA-N NC(=N)N.C(=N)N Chemical compound NC(=N)N.C(=N)N AEMHIRVQSGPNJA-UHFFFAOYSA-N 0.000 abstract 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract 1
- 244000046052 Phaseolus vulgaris Species 0.000 abstract 1
- 229960005091 chloramphenicol Drugs 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 206010013839 Duodenal ulcer haemorrhage Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical class CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108010079943 Pentagastrin Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960000444 pentagastrin Drugs 0.000 description 1
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
A cosmetic preparation for treating skin diseases comprises the following components in parts by weight of 1000 ml: 50-60 ml of coptis extract; 50-60 ml of honeysuckle extract; 8-12 g of chloramphenicol, metronidazole and formamidine guanidine respectively; 25-35 g of dimethyl sulfoxide; 2-3 g of hyaluronic acid; the balance was made up to 1000 ml with 7% ethanol. The invention can treat and protect the skin from fire, bacteria, inflammation, fat, penetration and moisture, prevent the skin from drying and wrinkling from all angles, and not only can be used for preventing dermatitis and being used as a cosmetic, but also has the function of treating skin diseases. The trial proves that the traditional Chinese medicine composition has good treatment effects on dry, rough and dry facial skin, stabbing pain, red swelling, blackhead scars, pruritus, various acnes and folliculitis, dermatitis caused by mites, young beans and the like, and has a comprehensive regulation and treatment effect on various skin intractable diseases.
Description
Technical field
The present invention relates to a kind of dermopathic cosmetic formulation of treatment and preparation method of having concurrently.
Background technology
Human for slow down aging, need the various cosmetic formulations of development.The main function of existing cosmetic formulation is a nursing skin, can not have the dermopathic function of treatment concurrently, therefore can't satisfy people's needs.Skin of face drying, rough, twinge, pruritus, red and swollen discomfort often appear in many people's skin, even the dermatitis that blackhead spot, acne, all kinds of acne and folliculitis, acarid cause occurs.Treat these dermopathic traditional drugs following a few class is arranged: one, oral medicine: 1, antimicrobial drug: tetracycline, erythromycin, gram force mycin, bactrim etc.; 2, anti-inflammatory agent: corticosteroid hormone, dapsone, ibuprofen class, cimetidine, Radix Salviae Miltiorrhizae Tabellae or injection etc.; 3, press down fat medicine and the normal medicine of short keratinization: vitamin A, the suitable retinoic acid (isomery retinoic acid) of D, 13-etc.; 4, anti-androgen medicine: diethylstilbestrol, oral contraceptive, potent gynotermone derivant; 5, vitamin E, B
2, B
6Deng; Two, medicine for external use: compound sulfur lotion, 5% sulphur ointment, 20% thiosulfonic acid sodium solution, 10% YUSHIZHI RUANGAO, 2～5% benzoyl peroxides (benzoyl peroxide ointment), antiiotic ointment etc.Medicine for external use needs and oral medicine is used, the patient usually wants outer simultaneously and wipes and several medicines for oral administration, each medicine function singleness, therapeutic process is very loaded down with trivial details, these oral medicine have side effect such as some gastrointestinal reactions, sexual hormone disturbance again in addition, sixty-four dollar question is that curative effect is not remarkable, is difficult to play ideal treatment.
Summary of the invention
The invention provides a kind of dermopathic cosmetic formulation of treatment and preparation method thereof that has concurrently, solve the problem that existing cosmetics can not be eliminated dermatopathy; And the existing treatment of solution dermatitis action of drug is single, therapeutic process is loaded down with trivial details, side effect is big, the inapparent technical problem of curative effect.
Technical scheme of the present invention: this dermopathic cosmetic formulation of treatment that has concurrently, contain broad-spectrum antibiotic, anaerobe resistant agent, solvent, it is characterized in that: its solvent is an ethanol, and antibiotics is chloromycetin, the anaerobe resistant agent is a metronidazole, with the proportioning of 1000 ml of formulation total amounts as
(1), 50～60 milliliters Rhizoma Coptidis leaching liquid;
(2), 50～60 milliliters Flos Lonicerae leaching liquid;
(3), the chloromycetin of 8～12 grams;
(4), the metronidazole of 8～12 grams;
(5), the cimetidine of 8～12 grams;
(6), the dimethyl sulfoxide of 25～35 grams;
(7), the hyaluronic acid of 2～3 grams;
(8), surplus adds to 1000 milliliters by 75% ethanol.
Above-mentioned Rhizoma Coptidis leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Rhizoma Coptidis to obtain in 24 hours.
Above-mentioned Flos Lonicerae leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Flos Loniceraes to obtain in 24 hours.
This preparation method that has the dermopathic cosmetic formulation of treatment concurrently is characterized in that preparation method is as follows:
A, preparation Rhizoma Coptidis leaching liquid: get Rhizoma Coptidis 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
B, preparation Flos Lonicerae leaching liquid: extracting honeysuckle 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
C, with each 8～12 gram of chloromycetin, metronidazole, cimetidine, in container, be mixed into the Western medicine mixed liquor with 75% ethanol;
D, the Western medicine mixed liquor among the above-mentioned steps C is mixed with Rhizoma Coptidis leaching liquid and Flos Lonicerae leaching liquid among step a, the b;
In e, the mixed liquor in steps d, add the dimethyl sulfoxide of 30 grams and the hyaluronic acid of 2～3 grams;
F, last adds to 1000 milliliters with 75% ethanol.
Above-mentioned chloromycetin can substitute with chlortetracycline or erythromycin.
This dermopathic cosmetic formulation of treatment that has concurrently of the present invention mainly comprises Rhizoma Coptidis, Flos Lonicerae, metronidazole, chloromycetin, cimetidine, dimethyl sulfoxide, hyaluronic acid and ethanol.Wherein: Rhizoma Coptidis, Flos Lonicerae are usually used in treating diseases such as catching a cold, get angry, are used for cosmetic formulation and have heat-clearing toxin-expelling functions preferably, and internal organs in the conditioning avoids endogenous fire to invade human body skin.
Add metronidazole in the prescription of the present invention, it not only has the effect of anaerobe extremely, also can kill acarid, diminishes inflammation.
Add chloromycetin in the prescription of the present invention, this broad spectrum antibiotic has good antiinflammation.
Cimetidine has another name called cimetidine, is the H2 receptor blocking agent, formerly is used to suppress histamine or pentagastrin stimulates the gastric acid secretion that causes, reduces gastric secretion and hydrogen ion concentration.Mainly treat diseases such as stomach, duodenal ulcer and upper gastrointestinal hemorrhage clinically with it.The present invention adopts this component to be used to suppress facial seborrhea, avoids seborrheic dermatitis.
Add dimethyl sulfoxide (DMSO) in the prescription of the present invention, molecular formula is (CH3) 2SO, can very strong penetrating power be arranged to human body, and other medicines are had rolling action, can increase the effect of drug transdermal administration, helps to absorb and improve curative effect.And have antiinflammatory, pain relieving, diuresis, calmness, blood circulation promoting and a wound healing effect.
(hyaluronicacid, HA), this chain polymeric acidic mucopolysaccharide is called as nature moisturizing factor, has good moisture preserving effect and hydrophilic to add hyaluronic acid in the prescription of the present invention.Be applied to skin and can form the transparent hydration shell of one deck viscoelasticity, has good water retention, can increase the moisture of keratodermatitis, improve drying and the skin that has occurred wrinkle, promote the skin-nourishing metabolism, making that skin is tender, smooth, wrinkle removing, prevent aging, is again the good transdermal absorption enhancer when preserving moisture.
The present invention is ingenious compound with above-mentioned several compositions; in ethanol, be prepared into a kind of dermopathic cosmetic formulation of treatment that has concurrently; from reduce internal heat, sterilization, antiinflammatory, press down fat, the several respects of permeating, preserve moisture are protected the skin multiple governance; prevent that from all angles xerosis cutis is wrinkling; not only can be used for preventing dermatitis, be used as cosmetics, also have the dermopathic function of treatment.Through probationary certificate, the dermatitis that facial xerosis cutis, rough, twinge, redness, blackhead spot, pruritus, all kinds of acne and folliculitis, acarid are caused and acne etc. all have better therapeutic effect, and the various skin pertinacious disease is had the synthesis treatment effect.
The part model case of proof curative effect of the present invention:
Zhou Aiping, woman, 42 years old, government functionary.It is coarse that face is felt for many years, drying, and the pore tingle uses multiple cosmetics to no effect.After using this product, dry symptom and pore sensation of pricking disappear, facial obvious delicate exquisiteness.
Susan, woman, 22 years old, university students.Facial comedo is more, often outbreak, and congestion and swelling pain, detumescence place has clear scar, and after use this product, comedo obviously reduces, and the blackhead cicatrix that stays also disappears.
Liu Mingming, woman, 26 years old, postgraduate.Facial dry pruritus, the long-term dependence used property of medicine Cleansing Foam etc., all do not have positive effect, and after use this product, dry pruritus transference cure does not re-use property of medicine Cleansing Foam etc., and face is obviously felt comfortable exquisiteness.
Liu Zizhong, man, 21 years old, university students.Face and cervical region acne symptom are heavier, use multiple property of medicine cosmetics and Drug therapy to no effect.Use after this product to begin to be clearly better in the week, be almost recovered after one month, after stopping using so far three wheat harvesting periods do not have rebound phenomenon.
Detect through disease prevention and control center, Nantong City, Jiangsu Province: its composition meets every regulation (No. the 2005018th, the survey report of seeing Appendix (woman's persona) searching) of Ministry of Public Health " cosmetics health standard " (version in 2002).
Usage of the present invention and consumption: based on beauty treatment, each is with once before early wash one's face every day back, the evening sleep.If skin has infection symptoms such as acne, can three to four times on the one.Preferably earlier affected part is cleaned and wiped driedly, dip in preparation wiping affected part three time with small brushes or cotton balls every day.The serious symptom person can five times, have no adverse reaction.Chinese medicine and western medicine of the present invention has antiinflammatory, sterilization, antidotal complex function in conjunction with preparation, can be used for senior cosmetics, and the various skin pertinacious disease is had the synthesis treatment effect.
The specific embodiment
Preferred embodiment with the preparation of 1000 ml of formulation total amounts:
Rhizoma Coptidis leaching liquid and Flos Lonicerae leaching liquid consumption all can be selected any number between 50～60 milliliters.Above-mentioned Rhizoma Coptidis leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Rhizoma Coptidis to obtain in 24 hours.Above-mentioned Flos Lonicerae leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Flos Loniceraes to obtain in 24 hours.
The metronidazole consumption can be selected any number between 8～12 grams.
The chloromycetin consumption can be selected any number between 8～12 grams.Also can use chlortetracycline, erythromycin or other antibiotics to substitute.
The cimetidine consumption can be selected any number between 8～12 grams.
The consumption of dimethyl sulfoxide can be selected any number between 25,30,35 grams or 25～35 grams.
Hyaluronic consumption can be selected any number between 2 grams, 2.5 grams, 3 grams or 2～3 grams.
Surplus adds to 1000 milliliters with 75% ethanol.
In a further embodiment, said preparation can consider to add materials such as cosmetic formulation spice commonly used, oils and fats, glycerol, lubricant, wetting agent.
This have concurrently the treatment dermopathic cosmetic formulation preparation method as follows:
A, preparation Rhizoma Coptidis leaching liquid: get Rhizoma Coptidis 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
B, preparation Flos Lonicerae leaching liquid: extracting honeysuckle 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
C, with each 8～12 gram of chloromycetin, metronidazole, cimetidine, in container, be mixed into the Western medicine mixed liquor with 75% ethanol;
D, the Western medicine mixed liquor among the above-mentioned steps C is mixed with Rhizoma Coptidis leaching liquid and Flos Lonicerae leaching liquid among step a, the b;
In e, the mixed liquor in steps d, add the dimethyl sulfoxide of 30 grams and the hyaluronic acid of 2～3 grams;
F, last adds to 1000 milliliters with 75% ethanol.
Claims (3)
1. one kind has the dermopathic cosmetic formulation of treatment concurrently, and it is characterized in that: its solvent is an ethanol, and antibiotics is chloromycetin, and the anaerobe resistant agent is a metronidazole, and is as follows with the proportioning of 1000 ml of formulation total amounts:
(1), 50～60 milliliters Rhizoma Coptidis leaching liquid;
(2), 50～60 milliliters Flos Lonicerae leaching liquid;
(3), the chloromycetin of 8～12 grams;
(4), the metronidazole of 8～12 grams;
(5), the cimetidine of 8～12 grams;
(6), the dimethyl sulfoxide of 25～35 grams;
(7), the hyaluronic acid of 2～3 grams;
(8), surplus adds to 1000 milliliters by 75% ethanol.
Above-mentioned Rhizoma Coptidis leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Rhizoma Coptidis to obtain in 24 hours.
Above-mentioned Flos Lonicerae leaching liquid is to be soaked in 2500 milliliter 75% ethanol by 500 gram Flos Loniceraes to obtain in 24 hours.
2. one kind has the preparation method for the treatment of dermopathic cosmetic formulation concurrently, it is characterized in that preparation method is as follows:
A, preparation Rhizoma Coptidis leaching liquid: get Rhizoma Coptidis 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
B, preparation Flos Lonicerae leaching liquid: extracting honeysuckle 500 grams, standby with 2500 milliliter 75% soak with ethanol 24 hours;
C, with each 8～12 gram of chloromycetin, metronidazole, cimetidine, in container, be mixed into the Western medicine mixed liquor with 75% ethanol;
D, the Western medicine mixed liquor among the above-mentioned steps C is mixed with Rhizoma Coptidis leaching liquid and Flos Lonicerae leaching liquid among step a, the b;
In e, the mixed liquor in steps d, add the dimethyl sulfoxide of 30 grams and the hyaluronic acid of 2～3 grams;
F, last adds to 1000 milliliters with 75% ethanol.
3. the preparation method that has the dermopathic cosmetic formulation of treatment concurrently according to claim 2 is characterized in that: above-mentioned chloromycetin substitutes with chlortetracycline or erythromycin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005388A CN100342872C (en) | 2005-09-16 | 2005-09-16 | A skin caring preparation for treating dermatoses, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005102005388A CN100342872C (en) | 2005-09-16 | 2005-09-16 | A skin caring preparation for treating dermatoses, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1739640A CN1739640A (en) | 2006-03-01 |
| CN100342872C true CN100342872C (en) | 2007-10-17 |
Family
ID=36092265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005102005388A Expired - Fee Related CN100342872C (en) | 2005-09-16 | 2005-09-16 | A skin caring preparation for treating dermatoses, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100342872C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943625B (en) * | 2006-10-30 | 2010-06-09 | 中国人民解放军第三军医大学第一附属医院 | Oral sterilizing liquid |
| CN104027278A (en) * | 2014-06-30 | 2014-09-10 | 周冠旻 | Depilatory paste |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586521A (en) * | 2004-07-23 | 2005-03-02 | 罗培省 | Healing agent for skin wound surface |
| CN1623572A (en) * | 2003-12-05 | 2005-06-08 | 韩播 | Anti-inflammation medicine |
-
2005
- 2005-09-16 CN CNB2005102005388A patent/CN100342872C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623572A (en) * | 2003-12-05 | 2005-06-08 | 韩播 | Anti-inflammation medicine |
| CN1586521A (en) * | 2004-07-23 | 2005-03-02 | 罗培省 | Healing agent for skin wound surface |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1739640A (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546928A (en) | TOPICAL FORMULATIONS CONTAINING CANNABIDIOL, METHODS FOR PREPARATION OF COMPOSITIONS AND USES THEREOF | |
| CN106902029A (en) | One kind makeup removing gel and preparation method thereof | |
| CN108653129B (en) | Skin dressing containing natural plant anti-allergy composition | |
| CN1052891C (en) | Gargle for aphtha | |
| CN102872241A (en) | Traditional Chinese medicinal composition for treating inflammatory dermatosis and preparation thereof | |
| CN1915351A (en) | Composition of Chinese traditional medicine in use for treating burn and scald, and product for resolving poxes, and preparation method | |
| CN105749333A (en) | Medical dressing of hyaluronic acid and preparation method of medical dressing | |
| KR20000046633A (en) | Composition for treatment of atopic dermatonosis | |
| CN100342872C (en) | A skin caring preparation for treating dermatoses, and its preparation method | |
| CN102764256A (en) | Ointment for treating acnes | |
| CN105056288B (en) | Medical hemorrhoid biological hydrogel functional dressings and preparation method thereof | |
| CN105497537A (en) | Medicine composition with skin whitening and tendering functions and preparing method thereof | |
| CN1850100A (en) | Medicinal composition for treating vagina disease | |
| KR102071586B1 (en) | Sheet mask pack composition for preventing of sensitive-skin and skin-trouble | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| CN112521389A (en) | Medicament and method for promoting wound healing | |
| CN101912376A (en) | Matrine vaginal effervescent tablets with bilayer structure and preparation method | |
| CN101049363A (en) | Composition of medication of skin prurigo agent, preparation method | |
| CN100337664C (en) | External-applied preparation for treating frostbite | |
| CN101028425A (en) | Medicine for treating acne | |
| CN1393221A (en) | Liquid medicine for treating acne | |
| CN116327669B (en) | Acne-removing composition with skin barrier repairing function and preparation method thereof | |
| CN103271930B (en) | A kind ofly treat pharmaceutical composition of diabetic foot that diabetes cause and acra dermatosis and preparation method thereof | |
| CN114712482B (en) | Astaxanthin-containing vagina cleaning antibacterial gel and preparation method thereof | |
| CN1058178C (en) | Cosmetics for preventing and curing acne dermatosis and its production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071017 Termination date: 20091016 |